US Patent No: 7,097,840

Number of patents in Portfolio can not be more than 2000

Methods of treatment using anti-ErbB antibody-maytansinoid conjugates

Stats

ALSO PUBLISHED AS: 20020001587
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
GENENTECH, INC.SOUTH SAN FRANCISCO, CA2224
IMMUNOGEN, INC.WALTHAM, MA90

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blattler, Walter Brookline, MA 5 60
Erickson, Sharon Hillsborough, CA 6 81
Schwall, Ralph Pacifica, CA 17 137
Sliwkowski, Mark San Carlos, CA 44 439

Cited Art

Patent Info (Count) # Cites Year
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (18)
4,265,814 Matansinol 3-n-hexadecanoate 23 1979
4,248,870 Maytansinoids and use 25 1979
4,256,746 Dechloromaytansinoids, their pharmaceutical compositions and method of use 28 1979
4,260,608 Maytansinoids, pharmaceutical compositions thereof and methods of use thereof 24 1979
4,294,757 20-O-Acylmaytansinoids 29 1980
4,322,348 Maytansinoids 29 1980
4,317,821 Maytansinoids, their use and pharmaceutical compositions thereof 22 1980
4,307,016 Demethyl maytansinoids 30 1980
4,308,268 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 24 1980
4,308,269 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 24 1980
4,309,428 Maytansinoids 24 1980
4,331,598 Maytansinoids 31 1980
4,362,663 Maytansinoid compound 28 1980
4,364,866 Maytansinoids 29 1980
4,361,650 Fermentation process of preparing demethyl maytansinoids 29 1981
4,371,533 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof 28 1981
4,424,219 9-Thiomaytansinoids and their pharmaceutical compositions and use 31 1982
5,217,713 Cytotoxic bispecific monoclonal antibody, its production and use 5 1992
 
Genentech, Inc. (6)
5,821,337 Immunoglobulin variants 217 1992
5,677,171 Monoclonal antibodies directed to the HER2 receptor 134 1994
6,054,297 Humanized antibodies and methods for making them 203 1995
5,725,856 Monoclonal antibodies directed to the HER2 receptor 121 1995
5,772,997 Monoclonal antibodies directed to the HER2 receptor 98 1995
5,840,525 Nucleic acids, vectors and host cells encoding heregulin 42 1995
 
IMMUNOGEN, INC. (3)
5,208,020 Cytotoxic agents comprising maytansinoids and their therapeutic use 100 1992
5,416,064 Cytotoxic agents comprising maytansinoids and their therapeutic use 71 1992
6,436,931 Cytotoxic agents comprising taxanes and their therapeutic use 21 2002
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (2)
5,747,261 Protein related to but distinct from EGF receptor and antibodies reactive therewith 39 1991
5,480,968 Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto 67 1992
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (2)
5,705,157 Methods of treating cancerous cells with anti-receptor antibodies 57 1994
5,824,311 Treatment of tumors with monoclonal antibodies against oncogene antigens 65 1994
 
The United States of America as represented by the Secretary of Agriculture (2)
4,313,946 Chemotherapeutically active maytansinoids from Trewia nudiflora 30 1981
4,315,929 Method of controlling the European corn borer with trewiasine 29 1981
 
AMGEN INC. (1)
5,783,186 Antibody-induced apoptosis 107 1995
 
BETH ISRAEL DEACONESS MEDICAL CENTER (1)
6,022,541 Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel 22 1997
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
4,968,603 Determination of status in neoplastic disease 161 1986
 
Cell Analysis Systems, Inc. (1)
5,514,554 Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy 60 1993
 
Creative BioMoelcules, Inc. (1)
5,877,305 DNA encoding biosynthetic binding protein for cancer marker 65 1994
 
NEUROTECH USA, INC. (1)
5,837,234 Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane 35 1995
 
Standard Oil Company (Indiana) (1)
4,450,254 Impact improvement of high nitrile resins 28 1982
 
United States of America (1)
5,183,884 DNA segment encoding a gene for a receptor related to the epidermal growth factor receptor 81 1989
 
Other [Check patent profile for assignment information] (1)
5,968,517 Process for extraction of proanthocyanidins from botanical material 13 1997

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
Genentech, Inc. (24)
7,846,441 Treatment with anti-ErbB2 antibodies 5 1998
7,892,549 Treatment with anti-ErbB2 antibodies 4 2003
7,862,817 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies 8 2005
7,449,184 Fixed dosing of HER antibodies 6 2005
7,618,631 Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs 7 2005
7,560,111 HER2 antibody composition 8 2005
7,501,122 Treatment with anti-ErbB2 antibody combinations 10 2005
7,498,030 Treatment with anti-ErbB2 antibodies and anti-hormonal compounds 10 2005
7,521,541 Cysteine engineered antibodies and conjugates 7 2005
7,537,931 Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies 11 2006
7,485,302 Treatment with anti-ErbB2 antibodies and chemotherapeutic agents 11 2006
8,163,287 Combination therapy of her expressing tumors 1 2006
8,076,066 Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy 2 2007
8,075,892 Treatment with anti-ErbB2 antibodies 3 2007
7,993,834 Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 antibody breast cancer therapy 4 2007
8,404,234 Fixed dosing of HER antibodies 0 2008
7,855,275 Cysteine engineered antibodies and conjugates 0 2009
8,309,300 Cysteine engineered antibodies and conjugates 0 2009
7,879,325 HER2 antibody composition 3 2009
8,372,396 Antibody formulations 0 2009
8,241,630 HER2 antibody composition 0 2011
8,309,087 Treatment with anti-ErbB2 antibodies 0 2011
8,425,908 Treatment with anti-ErbB2 antibodies 0 2011
8,440,402 Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy 0 2011
 
IMMUNOGEN, INC. (10)
8,088,387 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates 0 2004
7,501,120 Drug conjugate composition 2 2006
7,494,649 Drug conjugate composition 2 2006
8,198,417 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates 0 2007
8,163,888 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates 0 2007
7,989,598 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates 0 2007
8,337,856 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates 0 2007
8,093,358 Methods of treatment using anti-erbb antibody-maytansinoid conjugates 0 2007
8,012,485 Drug conjugate composition 1 2009
RE43899 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents 0 2012
 
SEATTLE GENETICS, INC. (4)
7,659,241 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease 11 2003
7,745,394 Monomethylvaline compounds capable of conjugation to ligands 9 2007
7,829,531 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease 7 2009
7,851,437 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease 7 2009
 
MERRIMACK PHARMACEUTICALS, INC. (1)
7,846,440 Antibodies against ErbB3 and uses thereof 0 2008

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 28, 2014
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 28, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00